Menu
Back to Journals » Breast Cancer: Targets and Therapy » Volume 16 » default
Breast Cancer: Targets and Therapy
ISSN: 1179-1314
- View all (490)
- Volume 16, 2024 (19)
- Volume 15, 2023 (79)
- Volume 14, 2022 (41)
- Volume 13, 2021 (58)
- Volume 12, 2020 (27)
- Volume 11, 2019 (32)
- Volume 10, 2018 (24)
- Volume 9, 2017 (64)
- Volume 8, 2016 (26)
- Volume 7, 2015 (36)
- Volume 6, 2014 (20)
- Volume 5, 2013 (13)
- Volume 4, 2012 (22)
- Volume 3, 2011 (16)
- Volume 2, 2010 (9)
- Volume 1, 2009 (4)
Archive: Volume 16, 2024
- default (19)
- Targeting Triple-Negative Breast Cancers: Modern Advancements and Future Directions (3)
Correlation Analysis of Digital Mammography, Ultrasonography, and Pathologic Features in Pure Invasive Micropapillary Carcinoma of the Breast (PIMPC)
Sui X, Feng P, Sun X, Liang P, Liu Y, Zhang G
Breast Cancer: Targets and Therapy 2024, 16:245-252
Published Date: 25 April 2024
Expression and Significance of LINC02418 in Breast Cancer
Zhou YH, Huang JY
Breast Cancer: Targets and Therapy 2024, 16:233-243
Published Date: 24 April 2024
Does the Dose of Standard Adjuvant Chemotherapy Affect the Triple-negative Breast Cancer Benefit from Extended Capecitabine Metronomic Therapy? An Exploratory Analysis of the SYSUCC-001 Trial
Chen Y, Li WX, Wu JH, Chen GH, Yang CM, Lu H, Wang X, Wang SS, Huang H, Cai L, Zhao L, Peng RJ, Lin Y, Tang J, Zeng J, Zhang LH, Ke YL, Wang XM, Liu XM, Zhang AQ, Xu F, Bi XW, Huang JJ, Li JB, Pang DM, Xue C, Shi YX, He ZY, Lin HX, An X, Xia W, Cao Y, Guo Y, Hong RX, Jiang KK, Zhong YY, Zhang G, Tienchaiananda P, Oikawa M, Yuan ZY, Chen QJ
Breast Cancer: Targets and Therapy 2024, 16:223-231
Published Date: 12 April 2024
Serum HER2 Level Predicts Therapeutic Efficacy and Prognosis in Advanced Breast Cancer Patients [Letter]
Syahruddin FI, Prihantono, Muis M
Breast Cancer: Targets and Therapy 2024, 16:221-222
Published Date: 11 April 2024
Identification and Validation of Novel Metastasis-Related Immune Gene Signature in Breast Cancer
Ma S, Hao R, Lu YW, Wang HP, Hu J, Qi YX
Breast Cancer: Targets and Therapy 2024, 16:199-219
Published Date: 12 April 2024
Therapy for Hormone Receptor-Positive, Human Epidermal Growth Receptor 2-Negative Metastatic Breast Cancer Following Treatment Progression via CDK4/6 Inhibitors: A Literature Review
Ye M, Xu H, Ding J, Jiang L
Breast Cancer: Targets and Therapy 2024, 16:181-197
Published Date: 10 April 2024
Serum HER2 Level Predicts Therapeutic Efficacy and Prognosis in Advanced Breast Cancer Patients
Wang S, Chen Y, Li W, Hao C, Zhang L, Zhao W, Shi Y, Tong Z
Breast Cancer: Targets and Therapy 2024, 16:163-179
Published Date: 3 April 2024
Amplifying Immune Responses: Microparticulate Vaccine Approach Against Breast Cancer
Ubowski MM, VanSice R, Marriott M, Yacobucci MJ, Chablani L
Breast Cancer: Targets and Therapy 2024, 16:149-162
Published Date: 28 March 2024
HER2 Low Expression in Primary Male Breast Cancer
Nobbe K, Erices-Leclercq M, Foerster F, Förster R, Baldus SE, Rudlowski C, Schröder L, Lubig S
Breast Cancer: Targets and Therapy 2024, 16:141-148
Published Date: 28 March 2024
ZNF217 Gene Copy Number as a Marker of Response to Standard Therapy Drugs According to ERα Status in Breast Cancer
Rangel N, Sánchez IL, Valbuena DS, Rondón-Lagos M
Breast Cancer: Targets and Therapy 2024, 16:127-139
Published Date: 15 March 2024
The Role of Ki-67 in HR+/HER2- Breast Cancer: A Real-World Study of 956 Patients
Ma Q, Liu YB, She T, Liu XL
Breast Cancer: Targets and Therapy 2024, 16:117-126
Published Date: 8 March 2024
Clinical Outcomes of Patients with HER2 Positive Metastatic Breast Cancer to the Brain, with First-Line Trastuzumab, Pertuzumab and Chemotherapy, in a Real-World Setting
Sharman Moser S, Apter L, Livnat I, Ginsburg R, Yarden A, Drori M, Drizon A, Chodick G, Siegelmann-Danieli N
Breast Cancer: Targets and Therapy 2024, 16:105-116
Published Date: 6 March 2024
An Analysis of Preoperative Inflammatory Indicators That Influence the Drainage Tube Retention Time in Patients with Breast Cancer Surgery
Li Q, Gao C, Zhao X, Li J, Shen Q, Chen L
Breast Cancer: Targets and Therapy 2024, 16:91-103
Published Date: 6 March 2024
GNPNAT1 is a Biomarker That Predicts a Poor Prognosis of Breast Cancer
Zhou Y, Xue W, Meng X, Bhandari A, Zeng H, KC R, Hirachan S, Xia E
Breast Cancer: Targets and Therapy 2024, 16:71-89
Published Date: 5 March 2024
Antibody-Drug Conjugates in Breast Cancer: A Comprehensive Review of How to Selectively Deliver Payloads
Monteiro MR, Nunes NCC, Junior AADS, Fêde ABDS, Bretas GDO, Souza CDP, Mano M, da Silva JL
Breast Cancer: Targets and Therapy 2024, 16:51-70
Published Date: 28 February 2024
Does Nipple-Ward Positive Margin Contribute to a Higher Rate of Re-Excision Procedures After a Lumpectomy with Pathology-Confirmed Positive Margins? A Retrospective Study
Bhimani F, Lin S, McEvoy M, Cavalli A, Obaid L, Chen Y, Gupta A, Pastoriza J, Shihabi A, Feldman S
Breast Cancer: Targets and Therapy 2024, 16:41-50
Published Date: 21 February 2024
Pretreatment Circulating Albumin, Platelet, and RDW-SD Associated with Worse Disease-Free Survival in Patients with Breast Cancer
Chen CC, Tang WH, Wu CC, Lee TL, Tsai IT, Hsuan CF, Wang CP, Chung FM, Lee YJ, Yu TH, Wei CT
Breast Cancer: Targets and Therapy 2024, 16:23-39
Published Date: 16 January 2024
Thyroid Hormone Changes Correlate to Combined Breast Cancer with Primary Thyroid Cancer
Jin J, Li J, Liu Y, Shi Q, Zhang B, Ji Y, Hu P
Breast Cancer: Targets and Therapy 2024, 16:15-22
Published Date: 9 January 2024
The Programmed Cell Death Ligand 1 and Lipocalin 2 Expressions in Primary Breast Cancer and Their Associations with Molecular Subtypes and Prognostic Factors
Ekemen S, Bilir E, Soultan HEA, Zafar S, Demir F, Tabandeh B, Toprak S, Yapicier O, Coban C
Breast Cancer: Targets and Therapy 2024, 16:1-13
Published Date: 3 January 2024